.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,087,217

« Back to Dashboard

Details for Patent: 7,087,217

Title:Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
Abstract: The present invention relates to the delivery of nonsteroidal antiinflammatory drugs (NSAIDs) through an inhalation route. Specifically, it relates to aerosols containing NSAIDs that are used in inhalation therapy. In a method aspect of the present invention, an NSAID is delivered to a patient through an inhalation route. The method comprises: a) heating a coating of an NSAID, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particle having less than 5% NSAID degradation products. In a kit aspect of the present invention, a kit for delivering an NSAID through an inhalation route is provided which comprises: a) a coating of an NSAID composition and b) a device for dispensing said coating as a condensation aerosol.
Inventor(s): Rabinowitz; Joshua D. (Mountain View, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Palo Alto, CA)
Filing Date:Jan 27, 2004
Application Number:10/766,279
Claims:1. A condensation aerosol for delivery of a drug selected from the group consisting of indomethacin, ketoprofen, celcoxib, rofecoxib, meclofenamic acid, fenoprofen, diflunisal, tolfenamic acid, naproxen, ibuprofen, flurbiprofen and nabumetone, wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

2. The condensation aerosol according to claim 1, wherein the condensation aerosol is formed at a rate greater than 10.sup.9 particles per second.

3. The condensation aerosol according to claim 2, wherein the condensation aerosol is formed at a rate greater than 10.sup.10 particles per second.

4. A method of producing a drug selected from the group consisting of indomethacin, ketoprofen, celcoxib, rofecoxib, meclofenamic acid, fenoprofen, diflunisal, tolfenamic acid, naproxen, ibuprofen, flurbiprofen and nabumetone in an aerosol form comprising: a. heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

5. The method according to claim 4, wherein the condensation aerosol is formed at a rate greater than 10.sup.9 particles per second.

6. The method according to claim 5, wherein the condensation aerosol is formed at a rate greater than 10.sup.10 particles per second.

7. The condensation aerosol according to claim 1, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.

8. The condensation aerosol according to claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

9. The condensation aerosol according to claim 1, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to 3 microns.

10. The condensation aerosol according to claim 1, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.

11. The condensation aerosol according to claim 10, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.

12. The condensation aerosol according to claim 1, wherein the solid support is a metal foil.

13. The condensation aerosol according to claim 1, wherein the drug is indomethacin.

14. The condensation aerosol according to claim 1, wherein the drug is ketoprofen.

15. The condensation aerosol according to claim 1, wherein the drug is celcoxib.

16. The condensation aerosol according to claim 1, wherein the drug is rofecoxib.

17. The condensation aerosol according to claim 1, wherein the drug is meclofenamic acid.

18. The condensation aerosol according to claim 1, wherein the drug is fenoprofen.

19. The condensation aerosol according to claim 1, wherein the drug is diflunisal.

20. The condensation aerosol according to claim 1, wherein the drug is tolfenamic acid.

21. The condensation aerosol according to claim 1, wherein the drug is naproxen.

22. The condensation aerosol according to claim 1, wherein the drug is ibuprofen.

23. The condensation aerosol according to claim 1, wherein the drug is flurbiprofen.

24. The condensation aerosol according to claim 1, wherein the drug is nabumetone.

25. The method according to claim 4, wherein the condensation aerosol is characterized by an MMAD of 0.1 to 5 microns.

26. The method according to claim 4, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

27. The method according to claim 4, wherein the condensation aerosol is characterized by an MMAD of about 0.2 to 3 microns.

28. The method according to claim 4, wherein the condensation aerosol is characterized by less than 5% drug degradation products by weight.

29. The method according to claim 28, wherein the condensation aerosol is characterized by less than 2.5% drug degradation products by weight.

30. The method according to claim 4, wherein the solid support is a metal foil.

31. The method according to claim 4, wherein the drug is indomethacin.

32. The method according to claim 4, wherein the drug is ketoprofen.

33. The method according to claim 4, wherein the drug is celcoxib.

34. The method according to claim 4, wherein the drug is rofecoxib.

35. The method according to claim 4, wherein the drug is meclofenamic acid.

36. The method according to claim 4, wherein the drug is fenoprofen.

37. The method according to claim 4, wherein the drug is diflunisal.

38. The method according to claim 4, wherein the drug is tolfenamic acid.

39. The method according to claim 4, wherein the drug is naproxen.

40. The method according to claim 4, wherein the drug is ibuprofen.

41. The method according to claim 4, wherein the drug is flurbiprofen.

42. The method according to claim 4, wherein the drug is nabumetone.

43. A condensation aerosol for delivery of indomethacin, wherein the condensation aerosol is formed by heating a thin layer containing indomethacin, on a solid support, to produce a vapor of indomethacin, and condensing the vapor to form a condensation aerosol characterized by less than 5% indomethacin degradation products by weight, and an MMAD of about 0.2 to 3 microns.

44. A condensation aerosol for delivery of ketoprofen, wherein the condensation aerosol is formed by heating a thin layer containing ketoprofen, on a solid support, to produce a vapor of ketoprofen, and condensing the vapor to form a condensation aerosol characterized by less than 5% ketoprofen degradation products by weight, and an MMAD of about 0.2 to 3 microns.

45. A condensation aerosol for delivery of celcoxib, wherein the condensation aerosol is formed by heating a thin layer containing celcoxib, on a solid support, to produce a vapor of celcoxib, and condensing the vapor to form a condensation aerosol characterized by less than 5% celcoxib degradation products by weight, and an MMAD of about 0.2 to 3 microns.

46. A condensation aerosol for delivery of rofecoxib, wherein the condensation aerosol is formed by heating a thin layer containing rofecoxib, on a solid support, to produce a vapor of rofecoxib, and condensing the vapor to form a condensation aerosol characterized by less than 5% rofecoxib degradation products by weight, and an MMAD of about 0.2 to 3 microns.

47. A condensation aerosol for delivery of meclofenamic acid, wherein the condensation aerosol is formed by heating a thin layer containing meclofenamic acid, on a solid support, to produce a vapor of meclofenamic acid, and condensing the vapor to form a condensation aerosol characterized by less than 5% meclofenamic acid degradation products by weight, and an MMAD of about 0.2 to 3 microns.

48. A condensation aerosol for delivery of fenoprofen, wherein the condensation aerosol is formed by heating a thin layer containing fenoprofen, on a solid support, to produce a vapor of fenoprofen, and condensing the vapor to form a condensation aerosol characterized by less than 5% fenoprofen degradation products by weight, and an MMAD of 0.2 to 3 microns.

49. A condensation aerosol for delivery of diflunisal, wherein the condensation aerosol is formed by heating a thin layer containing diflunisal, on a solid support, to produce a vapor of diflunisal, and condensing the vapor to form a condensation aerosol characterized by less than 5% diflunisal degradation products by weight, and an MMAD of about 0.2 to 3 microns.

50. A condensation aerosol for delivery of tolfenamic acid, wherein the condensation aerosol is formed by heating a thin layer containing tolfenamic acid, on a solid support, to produce a vapor of tolfenamic acid, and condensing the vapor to form a condensation aerosol characterized by less than 5% tolfenamic acid degradation products by weight, and an MMAD of about 0.2 to 3 microns.

51. A condensation aerosol for delivery of naproxen, wherein the condensation aerosol is formed by heating a thin layer containing naproxen, on a solid support, to produce a vapor of naproxen, and condensing the vapor to form a condensation aerosol characterized by less than 5% naproxen degradation products by weight, and an MMAD of about 0.2 to 3 microns.

52. A condensation aerosol for delivery of ibuprofen, wherein the condensation aerosol is formed by heating a thin layer containing ibuprofen, on a solid support, to produce a vapor of ibuprofen, and condensing the vapor to form a condensation aerosol characterized by less than 5% ibuprofen degradation products by weight, and an MMAD of about 0.2 to 3 microns.

53. A condensation aerosol for delivery of flurbiprofen, wherein the condensation aerosol is formed by heating a thin layer containing flurbiprofen, on a solid support, to produce a vapor of flurbiprofen, and condensing the vapor to form a condensation aerosol characterized by less than 5% flurbiprofen degradation products by weight, and an MMAD of about 0.2 to 3 microns.

54. A condensation aerosol for delivery of nabumetone, wherein the condensation aerosol is formed by heating a thin layer containing nabumetone, on a solid support, to produce a vapor of nabumetone, and condensing the vapor to form a condensation aerosol characterized by less than 5% nabumetone degradation products by weight, and an MMAD of about 0.2 to 3 microns.

55. A method of producing indomethacin in an aerosol form comprising: a. heating a thin layer containing indomethacin, on a solid support, to produce a vapor of indomethacin, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% indomethacin degradation products by weight, and an MMAD of about 0.2 to 3 microns.

56. A method of producing ketoprofen in an aerosol form comprising: a. heating a thin layer containing ketoprofen, on a solid support, to produce a vapor of ketoprofen, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% ketoprofen degradation products by weight, and an MMAD of about 0.2 to 3 microns.

57. A method of producing celcoxib in an aerosol form comprising: a. heating a thin layer containing celcoxib, on a solid support, to produce a vapor of celcoxib, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% celcoxib degradation products by weight, and an MMAD of about 0.2 to 3 microns.

58. A method of producing rofecoxib in an aerosol form comprising: a. heating a thin layer containing rofecoxib, on a solid support, to produce a vapor of rofecoxib, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% rofecoxib degradation products by weight, and an MMAD of about 0.2 to 3 microns.

59. A method of producing meclofenamic acid in an aerosol form comprising: a. heating a thin layer containing meclofenamic acid, on a solid support, to produce a vapor of meclofenamic acid, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% meclofenamic acid degradation products by weight, and an MMAD of about 0.2 to 3 microns.

60. A method of producing fenoprofen in an aerosol form comprising: a. heating a thin layer containing fenoprofen, on a solid support, to produce a vapor of fenoprofen, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% fenoprofen degradation products by weight, and an MMAD of about 0.2 to 3 microns.

61. A method of producing diflunisal in an aerosol form comprising: a. heating a thin layer containing diflunisal, on a solid support, to produce a vapor of diflunisal, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% diflunisal degradation products by weight, and an MMAD of about 0.2 to 3 microns.

62. A method of producing tolfenamic acid in an aerosol form comprising: a. heating a thin layer containing tolfenamic acid, on a solid support, to produce a vapor of tolfenamic acid, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% tolfenamic acid degradation products by weight, and an MMAD of about 0.2 to 3 microns.

63. A method of producing naproxen in an aerosol form comprising: a. heating a thin layer containing naproxen, on a solid support, to produce a vapor of naproxen, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% naproxen degradation products by weight, and an MMAD of about 0.2 to 3 microns.

64. A method of producing ibuprofen in an aerosol form comprising: a. heating a thin layer containing ibuprofen, on a solid support, to produce a vapor of ibuprofen, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% ibuprofen degradation products by weight, and an MMAD of about 0.2 to 3 microns.

65. A method of producing flurbiprofen in an aerosol form comprising: a. heating a thin layer containing flurbiprofen, on a solid support, to produce a vapor of flurbiprofen, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% flurbiprofen degradation products by weight, and an MMAD of about 0.2 to 3 microns.

66. A method of producing nabumetone in an aerosol form comprising: a. heating a thin layer containing nabumetone, on a solid support, to produce a vapor of nabumetone, and b. providing an air flow through the vapor to form a condensation aerosol characterized by less than 5% nabumetone degradation products by weight, and an MMAD of about 0.2 to 3 microns.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc